HopeStage
Back to all studies
CompletedNCT00145444

Ziprasidone compared with olanzapine for recent-onset psychosis

About this titleRead the official source — NCT00145444
Medication studyAges 18–40Belgium + NetherlandsSchizophrenia
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 40 years. Other eligibility criteria applied.

Listed locations
Antwerp and 6 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateMarch 2003
Recruitment status
Completed
Enrollment listed in the registry
100
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Sponsor type
Other organization
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Belgium, Netherlands
Age range
From 18 Years to 40 Years
Official registry ID
NCT00145444
Official title
Show the full official title

A Multicenter, Double-Blind, Randomized Trial Of Ziprasidone (80 - 160 Mg) Versus Olanzapine (10 - 20 Mg) In Patients With Recent-Onset Schizophrenia, Schizoaffective And Schizophreniform Disorder.

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Antwerp, Belgium · Duffel, Belgium · Kortenberg, Belgium

4 more locations
  • Ermelo, Netherlands
  • Groningen, Netherlands
  • Nijmegen, Netherlands
  • Utrecht, Netherlands

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Did this study involve medication?

Yes. The study involved medication, including olanzapine and ziprasidone.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 40 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies